Tandem Operating Cycle from 2010 to 2026

TNDM Stock  USD 19.89  0.13  0.66%   
Tandem Diabetes Operating Cycle yearly trend continues to be very stable with very little volatility. Operating Cycle is likely to grow to 262.28 this year. During the period from 2010 to 2026, Tandem Diabetes Operating Cycle quarterly data regression pattern had sample variance of  93,092 and median of  190.52. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
190.52
Current Value
262.28
Quarterly Volatility
305.10931724
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Tandem Diabetes financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tandem Diabetes' main balance sheet or income statement drivers, such as Depreciation And Amortization of 172.6 K, Interest Expense of 6.4 M or Selling General Administrative of 470.7 M, as well as many indicators such as Price To Sales Ratio of 2.74, Dividend Yield of 0.0 or PTB Ratio of 5.14. Tandem financial statements analysis is a perfect complement when working with Tandem Diabetes Valuation or Volatility modules.
  
Build AI portfolio with Tandem Stock
Check out the analysis of Tandem Diabetes Correlation against competitors.
Evaluating Tandem Diabetes's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Tandem Diabetes Care's fundamental strength.

Latest Tandem Diabetes' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Tandem Diabetes Care over the last few years. It is Tandem Diabetes' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tandem Diabetes' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Tandem Operating Cycle Regression Statistics

Arithmetic Mean321.58
Geometric Mean244.06
Coefficient Of Variation94.88
Mean Deviation224.33
Median190.52
Standard Deviation305.11
Sample Variance93,092
Range823
R-Value(0.66)
Mean Square Error56,136
R-Squared0.43
Significance0
Slope(39.84)
Total Sum of Squares1.5M

Tandem Operating Cycle History

2026 262.28
2025 190.52
2024 165.67
2023 203.22
2022 156.73
2021 134.12
2020 157.74

About Tandem Diabetes Financial Statements

Tandem Diabetes investors utilize fundamental indicators, such as Operating Cycle, to predict how Tandem Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle 190.52  262.28 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Check out the analysis of Tandem Diabetes Correlation against competitors.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Will Health Care Equipment & Supplies sector continue expanding? Could Tandem diversify its offerings? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Tandem Diabetes data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
(0.37)
Earnings Share
(3.03)
Revenue Per Share
15.083
Quarterly Revenue Growth
0.022
Return On Assets
(0.06)
Understanding Tandem Diabetes Care requires distinguishing between market price and book value, where the latter reflects Tandem's accounting equity. The concept of intrinsic value—what Tandem Diabetes' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Tandem Diabetes' price substantially above or below its fundamental value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tandem Diabetes' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.